With some traditional drug companies starved for growth, Cramer thinks smaller biotechs may be in play.» Read More
Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.
Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
After a hot streak, biotech stocks lose value as clinical trials fail.
Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F. TheStreet.com examines Baupost Group's holdings.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?
Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.
So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500. While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown.